Why the study?
Does primary care prescribing adhere to recommendations for concomitant PPI use in patients taking regular low-dose aspirin with increased GI risk?
Does primary care prescribing adhere to recommendations for concomitant PPI use in patients taking regular low-dose aspirin with increased GI risk?
More than half of primary care patients at increased risk for gastrointestinal complications while taking low-dose aspirin do not receive guideline-recommended regular proton-pump inhibitor therapy.
Answers are grounded in this paper and cite their sources.
May increase preventable GI events in aspirin users; leaves open whether targeted interventions improve adherence and outcomes.
OBJECTIVE: Determine the adherence to recommendations of concomitant proton-pump inhibitor (PPI) treatment in regular low-dose of aspirin (LDASA) users, taking factors associated with the probability of receiving a PPI into account. DESIGN: Cohort study. SETTING: Data were obtained from 120 Dutch primary care centres participating in the Netherlands Information Network of Primary Care (LINH). PARTICIPANTS: Patients 18 years and older who were regularly prescribed LDASA (30-325 mg) in 2008-2010 were included. MAIN OUTCOME MEASURES: Regular medication use was defined as receiving each consecutive prescription within 6 months after the previous one. Based on national guidelines, we categorised LDASA users into low and high gastrointestinal (GI) risk. A multilevel multivariable logistic regression analysis was applied to identify patient characteristics that influenced on the probability of regular PPI prescriptions. RESULTS: We identified 12 343 patients who started LDASA treatment, of whom 3213 (26%) were at increased risk of GI complications. In this group, concomitant regular use of PPI was 46%, 36% did not receive PPI prescriptions and 18% obtained prescriptions irregularly (p<0.0001). The chance to obtain regularly PPI prescriptions versus no PPI was significantly influenced by, among others, previous GI complications (OR 13.9 (95% CI 11.8 to 16.4)), use of non-steroidal anti-inflammatory drugs (OR 5.2 (4.3 to 6.3)), glucocorticosteroids (6.1 (4.6 to 8.0)), selective serotonin reuptake inhibitors (9.1 (6.7 to 12.2)), drugs for functional GI disorders (2.4 (1.9 to 3.0)) and increased age. CONCLUSIONS: Primary care physicians do not fully adhere to the current recommendations to prescribe PPIs regularly to LDASA users with an increased GI risk. More than 50% of the patients with an increased GI risk are not treated sufficiently with a concomitant PPI, increasing the risk of GI side effects. This finding underlines the necessity to consider merging recommendations into one common, standard and frequently used recommendation by primary care physicians.
No takes yet. Share an insight, caveat, or question.
Jong et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: